Cargando…

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer

Immunotherapy has been focused on by many oncologists and researchers. While, due to technical biases of absolute quantification, few traditional biomarkers for anti-PD-1 immunotherapy have been applied in regular clinical practice of non-small cell lung cancer (NSCLC). Therefore, there is an urgent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chengming, Wang, Sihui, Zheng, Sufei, Xu, Fei, Cao, Zheng, Feng, Xiaoli, Wang, Yan, Xue, Qi, Sun, Nan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640493/ https://www.ncbi.nlm.nih.gov/pubmed/34868057 http://dx.doi.org/10.3389/fimmu.2021.782106

Ejemplares similares

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma
por: Liu, Chengming, et al.
Publicado: (2022)

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Absolute quantification and characterization of oxylipins in lupus nephritis and systemic lupus erythematosus
por: He, Jingquan, et al.
Publicado: (2022)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma
por: Xin, Hongjie, et al.
Publicado: (2023)

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer
por: Yu, Sihui, et al.
Publicado: (2021)

Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma
por: Zeng, Yu, et al.
Publicado: (2022)

NETQUANT: Automated Quantification of Neutrophil Extracellular Traps
por: Mohanty, Tirthankar, et al.
Publicado: (2018)

Neutrophil extracellular traps in tumor progression and immunotherapy
por: Yan, Meina, et al.
Publicado: (2023)

Editorial: Extracellular traps in cancer immunity and immunotherapy
por: Rahat, Michal A., et al.
Publicado: (2023)

A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma
por: Li, Qilin, et al.
Publicado: (2022)

Computational Methodologies for the in vitro and in situ Quantification of Neutrophil Extracellular Traps
por: van Breda, Shane V., et al.
Publicado: (2019)

Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
por: Zhu, Mingchuang, et al.
Publicado: (2022)

Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
por: Zhu, Mingchuang, et al.
Publicado: (2022)

TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2
por: Wang, Feng, et al.
Publicado: (2021)

Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer
por: Hou, Yidan, et al.
Publicado: (2023)

An estrogen response-related signature predicts response to immunotherapy in melanoma
por: Lin, Min, et al.
Publicado: (2023)

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy
por: Wang, Zheng, et al.
Publicado: (2022)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer
por: Wang, Ke-wei, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Identification and Validation in a Novel Quantification System of Ferroptosis Patterns for the Prediction of Prognosis and Immunotherapy Response in Left- and Right-Sided Colon Cancer
por: Zhang, Heng-Chun, et al.
Publicado: (2022)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
por: Yan, Zheng, et al.
Publicado: (2021)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
por: Liu, Dan, et al.
Publicado: (2023)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies
por: Chen, Lei, et al.
Publicado: (2022)

The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma
por: Li, Xizhe, et al.
Publicado: (2022)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
por: Hou, Bo, et al.
Publicado: (2023)

Pathogen-Derived Nucleases: An Effective Weapon for Escaping Extracellular Traps
por: Liao, Chengshui, et al.
Publicado: (2022)

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy
por: Lin, Mao, et al.
Publicado: (2022)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lekd5ehg7oq1r8lduq43ubngm0